Skip to main content
Publications
Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, Galindo-Suarez RM, Guerino J, Mejia A, Mujoomdar M, Ollendorf D, Ronquest N, Torbica A, Tsiao E, Watkins J, Yeung K, ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems collaborators. Corrigendum to Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report: [Value in Health 25 (2022) 1257-1267/3488]. Value Health. 2023 Dec;26(12):1811. doi: 10.1016/j.jval.2023.06.010
Handels R, Herring W, Kamgar F, Gustavsson A, Skoldunger A, Wimo A, Tate A, Winblad B, Stellick CB, Bruck C, Green C, de Kok I, Hlavka J, Mar J, Urbich M, Soto-Gordoa M, Pemberton-Ross P, Aye S, Jonsson L, workshop 2023 Participants I. IPECAD modeling workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease and related dementias. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S419. doi: 10.1016/j.jval.2023.09.2194
Li X, Hodgson D, Flaig J, Kieffer A, Herring WL, Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P, REspiratory Syncytial virus Consortium in EUrope (RESCEU) Investigators. Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study. Value Health. 2023 Apr;26(4):508-18. doi: 10.1016/j.jval.2022.11.014
Mellott C, Jaworski R, Carrico J, Clinkscales M, Talbird S, Dobrowolska I, Golicki D, Tsoumani E, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S117. doi: 10.1016/j.jval.2022.09.568
Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Health and economic impact of a novel 3-antigen vaccine for the prevention of hepatitis B in adults in Germany: a cost-effectiveness analysis. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S135. doi: 10.1016/j.jval.2022.09.649
Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Cost-effectiveness and epidemiological impact of a novel 3-antigen vaccine for the prevention of Hepatitis B in adults in the United Kingdom. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. doi: 10.1016/j.jval.2022.09.782
Li X, Hodgson D, Flaig J, Kieffer A, Herring W, Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P. Cost-effectiveness of Respiratory Syncytial Virus (RSV) prevention interventions in children: a model comparison study. Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec; 25(12S):S178. doi: 10.1016/j.jval.2022.09.861